Quantum Blue® Reader 3rd Generation

The Quantum Blue® 3rd generation is a state-of-the-art camera based  lateral flow test cassette reader. It uses the latest image analysis technology. The touch screen allows for an intuitive user interface with easy step-by-step tutorial screens. The interface offers the connection to Laboratory and Hospital Information Systems (LIS/HIS).


Calprotectin is the best marker to discriminate between organic (IBD) and non-organic bowel disease (IBS). Calprotectin is a reliable indicator of inflammation in several pathologies. Patients suffering from IBS do not have increased faecal calprotectinvalues. Faecal calprotectin concentrations, as measured by the BÜHLMANN calprotectin assays, are significantly elevated in patients with IBD and correlate well with endoscopic and histological assessment of disease activity.

Therapeutic Drug Monitoring

Over the past two decades great improvements in therapy of chronic inflammatory diseases have been made. The rise of TNFα biologics like adalimumab and infliximab has been a great step forward to ameliorating disease course and keep inflammations at remission levels for prolonged periods of time. Patients with suboptimal drug concentrations have worse outcomes than those with adequate drug levels.  Therapeutic drug monitoring (TDM) for adalimumab and infliximab has a great potential for the management of anti TNF therapy.

Quantum Blue® Reader 2nd Generation

The Quantum Blue® product line is based on lateral flow technology,offering quantitative results within minutes.


The Quantum Blue® CRP test allows for a rapid determination of serum CRP within 15 minutes. It is an ideal tool to accompany the calprotectin determination for establishing an IBD patient inflammation profile during the course of the disease. The combination of the two markers has shown to increase the specificity for detecting inflammation in Crohn’s disease. The ease of use and speed of these two tests on the Quantum Blue® platform make this technology a very convenient addition to the therapy monitoring chronic inflammation of the gut.


MRP8/14 is an early and sensitive marker of inflammation and is released immediately in response to local inflammation. In contrast, other inflammatory markers are generated by downstream pathways and require de novo synthesis. Therefore, MRP8/14 is an ideal target for monitoring disease activity of Rheumatoid Arthritis. The MRP8/14 assays by BÜHLMANN allow for precise and sensitive measurement of this important marker.


The measurement of calprotectin in ascitic fluid provides reliable and rapid results using the Quantum Blue® technology. It provides a solution for point of care detection of spontaneous bacterial peritonitis, which is an important cause of morbidity and mortality in cirrhotic patients with ascites.